Antiangiogenic therapy for breast cancer - Wikidata - wikimedia - TriplyDB

Antiangiogenic therapy for breast cancer

Antiangiogenic therapy for breast cancer

http://www.wikidata.org/entity/Q34989039

about

HET0016, a selective inhibitor of 20-HETE synthesis, decreases pro-angiogenic factors and inhibits growth of triple negative breast cancer in mice Anti-Invasive and Anti-Proliferative Synergism between Docetaxel and a Polynuclear Pd-Spermine Agent Clinical response to sunitinib as a multitargeted tyrosine-kinase inhibitor (TKI) in solid cancers: a review of clinical trials.Angiogenesis in Breast Cancer and its Correlation with Estrogen, Progesterone Receptors and other Prognostic Factors.68Ga-PSMA-HBED-CC PET imaging in breast carcinoma patients.Trials of bevacizumab in breast cancer--a safety review.Assessing breast cancer angiogenesis in vivo: which susceptibility contrast MRI biomarkers are relevant?Role of NF-κB activation in matrix metalloproteinase 9, vascular endothelial growth factor and interleukin 8 expression and secretion in human breast cancer cells.Hypertensive diseases in pregnancy and subsequent lower risk of breast cancer: the common immune and antiangiogenic profile.

P2860

Q21131825-BA1FC99F-FC23-4DC0-898F-74C53F954CCA Q28553698-B14224F4-444D-47E0-93A3-27AE93F307BB Q33633431-881AD696-86CE-43D0-BE6F-6555E5F3CA00 Q35139611-78E7EF01-7934-40E2-B404-AA91EA57936D Q37662685-DFB4C073-6312-43C9-948A-296BD6071B99 Q37887823-41360399-6A90-4D35-A172-195625558B17 Q39229419-8EDA1173-7687-4B95-9FED-20CAA83C4CA1 Q39255458-A119875F-87BE-4D61-B158-F309C3F92D27 Q42348070-964F351C-275F-47D5-AFC9-25BD86AC0295

P2860

Antiangiogenic therapy for breast cancer

http://www.wikidata.org/entity/Q34989039

description

2010 nî lūn-bûn

@nan

2010 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Antiangiogenic therapy for breast cancer

@ast

Antiangiogenic therapy for breast cancer

@en

Antiangiogenic therapy for breast cancer

@nl

type

label

Antiangiogenic therapy for breast cancer

@ast

Antiangiogenic therapy for breast cancer

@en

Antiangiogenic therapy for breast cancer

@nl

prefLabel

Antiangiogenic therapy for breast cancer

@ast

Antiangiogenic therapy for breast cancer

@en

Antiangiogenic therapy for breast cancer

@nl

P1433

Q34989039-95FDB1D3-AEED-4430-9BD5-E9F6BF9148CF

P1476

Q34989039-7CF58F00-30A1-4AAE-A3C4-FD84E88D5AAB

P2093

Q34989039-01A86FAC-5895-4C99-899A-5AF81D9AA71A

Q34989039-17682968-3A15-4BB2-85AB-4A526288D7F8

Q34989039-B03486E5-5DE4-4635-9D0E-1B0063629A76

Q34989039-C30B91AC-BC04-43F7-A70B-027FF6F07D54

P2860

Q34989039-0318D4AA-58E8-47BB-89A6-F773537FE80C

Q34989039-062F6155-8D02-4508-ADEB-FB2F2865841F

Q34989039-06F90ADB-023B-49D7-842A-D98AD2D1CF4A

Q34989039-0E5D0EDA-BBA3-4E53-B319-CC1F96A077D4

Q34989039-1CF56903-5241-4934-A2A2-7032F46D45E4

Q34989039-1F5F4EDE-883C-422D-B011-A099219F1E6A

Q34989039-1FDB5874-1D21-4BE4-8D08-21DB39A5E04F

Q34989039-23190229-943F-42A3-BC94-1F2A02B363CA

Q34989039-23EFFFA6-2D5D-47DC-A662-723128F92861

Q34989039-2464474F-AD92-4582-B2BF-AA859A444AE7

P2888

Q34989039-C4324C8C-D62C-4BC1-BA95-DFC80EAC619F

P304

Q34989039-19BA207B-E0DF-4D4E-A42A-07D7E3408A2A

P31

Q34989039-48EE361A-1B17-4CF0-AFED-B1154CC17602

Q34989039-B97565BE-A7F4-4466-AAB4-1933267381AC

P356

Q34989039-9AF87F28-3969-474F-A823-7CBD4FB1F3E7

P433

Q34989039-7B286029-A982-46BE-A396-57DA8D431CE7

P478

Q34989039-6ED1552F-1358-4158-9899-2BA80118DE43

P577

Q34989039-49C0CD2A-557A-4660-A113-D4E03F2D3477

P5875

Q34989039-102E9E9A-D37B-4567-B4EA-360C3DFB0B3A

P6179

Q34989039-E062E025-A93D-4D48-B022-D2F22C7FBCCE

P698

Q34989039-946E15D7-FDB7-4073-AA67-BA1CD4978BD6

P921

Q34989039-83083710-44C7-4D70-812C-3A47E5A5C34C

P932

Q34989039-44A2E7F5-61A0-47CD-B1DC-8B84CD138ED8

P356

P1433

Breast Cancer Research

P1476

Antiangiogenic therapy for breast cancer

@en

P2093

Claus Kamby

http://www.w3.org/2001/XMLSchema#string

Dorte Lisbet Nielsen

http://www.w3.org/2001/XMLSchema#string

Jon Lykkegaard Andersen

http://www.w3.org/2001/XMLSchema#string

Michael Andersson

http://www.w3.org/2001/XMLSchema#string

P2860

Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels

VEGF-Trap: a VEGF blocker with potent antitumor effects.

Modes of resistance to anti-angiogenic therapy

Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis

A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer

PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration

mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer

Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer.

P2888

P304

209

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/BCR2642

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

12

http://www.w3.org/2001/XMLSchema#string

P577

2010-09-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

47741794

http://www.w3.org/2001/XMLSchema#string

P6179

1000882498

http://www.w3.org/2001/XMLSchema#string

P698

21067536

http://www.w3.org/2001/XMLSchema#string

P921

P932

3096961

http://www.w3.org/2001/XMLSchema#string